ABX-001

ABX-001 is an arenavirus-based non-lytic viroimmunotherapy (intravenous) from Abalos Therapeutics. An arenavirus-based candidate given into a vein, designed to persist and replicate in cancer cells and antigen-presenting cells without destroying them, triggering innate and adaptive immune responses against the tumour. Its furthest stage is phase 1, for advanced solid tumours (refractory or relapsed). ClinicalTrials.gov registers it in one study linked below. First patient dosed 23 October 2025 (company release); NCT07231458 recruiting. Whether it works in people has not been established unless a trial below reports it.